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A family of mutant proteins related to calmodulin (CaM) has been produced using cDNA constructs in bacterial expres- 
sion vectors. The new proteins contain amino acid substitutions in Ca *+-binding domains I, II, both I and II, or both 
II and IV. The calmodulin-like proteins have been characterized with respect to mobility on SDS-polyacrylamide gels, 
Ca2+-dependent enhancement of tyrosine fluorescence, and abilities to activate the CaM-dependent phosphatase calci- 
neurin. These studies suggest that an intact Ca *+-binding domain II is minimally required for full activation of calci- 
neurin. 
Calmodulin; Calcineurin; Mutagenesis 
1. INTRODUCTION 
Calmodulin (CaM) regulates the activity of a 
large number of enzymes. Studies using 
chemically-modified [l-7] or site-specifically 
mutated [S-12] CaMs have revealed that in- 
dividual enzymes are differentially affected by any 
given alteration. The protein phosphatase 
calcineurin is only partially activated by a CaM to 
which a phenothiazine has been covalently attach- 
ed [ 131. Similarly calmodulin-like (CaML) proteins 
(CaML16 and CaML19) have been described that 
can activate calcineurin only partially but would 
maximally activate cGMP phosphodiesterase 
(PDE) or myosin light-chain kinase (MLCK) [9]. 
CaML proteins are the bacterially produced 
product of a chicken calmodulin pseudogene that 
contains 19 amino acid substitutions relative to 
calmodulin [14]. These substitutions exist in 
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Ca2+-binding domains I, II and IV. In order to 
define the domain containing the substitutions that 
results in a protein with partial agonist activity 
relative to calcineurin, a family of new proteins has 
been produced by combining portions of the 
pseudogene and two CaM cDNAs. The new CaML 
proteins contain amino acid substitutions in Ca2+ 
binding domains I, II, both I and II, or both II and 
IV. Analysis of these proteins shows that domain 
II contains the mutations that result in reduced 
ability to act as an agonist of calcineurin. 
2. EXPERIMENTAL 
2.1. Construction of bacterial expression vectors for Cah4L 
proteins 
The expression plasmids for the new CaML proteins were 
constructed from previously described cDNAs for normal eel 
CaM (pCM116) [15], normal chicken CaM (pcB12) [16], a 
chicken processed CaM pseudogene (CMl) [17], and the expres- 
sion plasmid for CM1 (pCaML19) [9]. Enzymes were obtained 
from Bethesda Research Laboratories and were used according 
to the manufacturer’s recommendations. DNA fragments were 
isolated using either low-melting agarose or 5% PAGE as 
described below. 
2.1.1. Construction of pCaML13 
Ca’+-binding domain I was isolated from pCM116 as the 138 
base-pair (bp) Sau3A/PstI subfragment of the 171 bp PstI frag- 
ment. Ca*+-binding domains II and III were isolated from 
pCaMLl6. pCaML16 was linearized with PstI, 
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dephosphorylated with bacterial alkaline phosphatase (BAP) 
and then digested with BcfI to yield a 229 bp fragment. Using 
Td DNA ligase, these two small fragments were ligated into a 
BAP-treated 3232 bp &/I fragment of pCaML16. The 3232 bp 
fragment contains Ca *+-binding domain IV in a pUC8 vector 
181. 
2.1.2. Construction of pCaML3A 
A 712 bp Pstl fragment of pCM116 which contained the 
Ca’+-binding domains II, III, and IV was ligated into 
pCaML16 which had been linearized with Pstl and treated with 
BAP. The pCaML16 contributed Ca*‘-binding domain 1 in a 
pUC8 vector. 
2.1.3. Construction of the intermediate pCaMLl3A 
A 121 bp Sau3A subfragment of a 400 bp AIuI fragment of 
pCMl16 containing Ca *+-binding domain IV was ligated into 
pCaML19 which had been linearized with Bcfi and 
dephosphorylated with calf intestinal phosphatase (CIP). 
pCaML19 is in the vector pBR322 and contributes the 
Ca*+-binding domains I, II, and III to the new coding region. 
2.1.4. Construction of pCaMLl0 
A 154 bp Pstl/BamHI fragment containing Ca*‘-binding do- 
mains I and II of pCaML16 was ligated into the large 
PstI/BamHI fragment of pCaML13A. pCaML13A contributed 
Ca*+-binding domains III and IV. 
2.1.5. Construction of pCaML7 
A 154 bp PstI/BamHI fragment containing the first two 
Ca*+-binding domains of pCaML13 was ligated into the large 
PstI/BamHI fragment of pCaML13A. pCaML13A contributed 
the last two Ca*+-binding domains. 
2.2. Purification of bacterially expressed CaM proteins 
Proteins were purified from bacterial lysates using differen- 
tial chromatography on phenyl-Sepharose in the presence and 
absence of Ca*+ as described 181. The proteins were further 
purified using HPLC. Samples were applied to a TSK- 
DEAE-5PW (BioRad) column (75 mm x 7.5 cm) and then 
eluted with a linear gradient from O-O.5 M NaCl in 10 mM 
Tris-HCl, pH 7.5, 1 mM DTT, 0.1 mM EDTA. 
2.3. Electrophoresis 
Electrophoresis of DNA fragments was performed either on 
1% low-melting point agarose or 5% PAGE [8]. DNA 
fragments were isolated using ‘NACS’ prepacked columns ac- 
cording to the manufacturer’s recommendations (Bethesda 
Research Laboratories). 
Protein electrophoresis was performed on 15% SDS-PAGE 
according to the method of Laemmli [18]. The protein samples 
were solubilized in sample buffer containing either 5 mM CaCl2 
or 5 mM EDTA. 
2.4. Tyrosine fluorescence 
Tyrosine fluorescence was measured using an Aminco 
SPF-500 Ratio Spectrofluorometer. Solutions containing 
0.2 mg protein per ml 50 mM Tris-HCl, pH 7.5, 150 mM NaCI, 
0.2 mM EGTA (22°C) were excited at 275 nm and fluorescent 
emission was monitored at 307 nm. Ca*+ solutions were 
prepared by dilution from Orion standard Ca*+ solution 
(0.1 M). Free Ca*+ concentrations were calculated using a com- 
puter program developed by Goldstein [19]. 
2.5. Calcineurin assays 
Calcineurin was prepared and assayed as described by 
Newton et al. using p-nitrophenyl phosphate as the substrate 
1201. 
3. RESULTS AND DISCUSSION 
The schemes for the construction of the four 
new expression plasmids (pCaML3A, pCaML7, 
pCaML 10, and pCaML13) are described in section 
2 and shown in fig.1. The resulting plasmids were 
used to transform the E. co/i strain JM103. The 
structures of the newly constructed CaML cDNAs 
were confirmed by restriction and sequence 
analysis. The location of amino acid sequence dif- 
ferences between the proteins encoded by the new- 
ly constructed CaML cDNAs and pCaM23 are 
indicated by the open (conservative changes) and 
closed (non-conservative changes) circles along the 
bar diagrams in fig.1. Conforming to the 
nomenclature introduced by Putkey et al. [9], the 
CaML plasmids and their corresponding protein 
products are named to indicate the number of 
amino acid differences with respect to normal 
chicken CaM. 
For each plasmid, 6 1 of bacterial culture grown 
in the presence of the inducer isopropyl-&D- 
thiogalactoside (IPTG) were used as the source of 
the bacterially synthesized proteins. Protein 
purifications were performed as described in sec- 
tion 2 and yielded >30 mg of each CaM or CaML 
protein. SDS-PAGE was performed in the 
presence or absence of Ca’+. The gel in fig.2 shows 
the relative mobilities of CaM23 and of the CaML 
proteins. In the absence of Ca2+, all the proteins 
co-migrated with CaM23. CaM23 and CaML7 are 
shown as representative proteins. In the presence 
of Ca2+, all the proteins demonstrated an ion- 
dependent shift in mobility. The extent of the in- 
duced migration shift, however, is related to the 
number of amino acid substitutions in the CaML 
protein. CaM23 and CaML3A which has only 
three amino acid substitutions in Ca’+-binding do- 
main I show the greatest shifts. CaML16 and 
CaML13 show the least effect of Ca2+ on the 
migration of SDS-PAGE, and CaMLlO and 
CaML7 show an intermediate effect. 
CaM shows a characteristic enhancement of 
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Fig. 1. Construction of pCaML expression plasmids. Expression vectors for calmodulin-like proteins were constructed as described in 
section 2. The amino acid substitutions indicated by the open (conservative) and closed (non-conservative) circles are: domain 1 - 
K*‘---rR, T26-+C, and K3’--+M; domain II - l’*~V, N”+G, NW-S, T7’-+S, M”hL, K”+R, and T”--+S; domain 
IV - R’26__*K, I’30---*C, D”‘--tN, GL3*--rR, and Ai4’--+Q. 
tyrosine fluorescence emission at 307 nm when 
CaM is excited at 275 nm in the presence of Ca2+ 
vs in the absence of Ca2+ [21]. Fig.3 shows the 
ratio of the relative fluorescence in the presence of 
Ca2+ to the relative fluorescence in the absence of 
Ca2+ as a function of free Ca2+ concentration. The 
curve derived for CaM23 is identical to the curves 
derived for CaML3A, CaML7, and CaMLlO (not 
shown). Those curves, however, are distinctly dif- 
ferent from the ones generated for CaML13 and 
CaML16, both of which contain amino acid 
substitutions in Ca2+-binding domain IV. The 
reduction of the Ca2+-induced enhancement of 
tyrosine over physiologic ranges of Ca2+ concen- 
trations appears to be specifically related to 
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changes in the amino acid sequence in 
Ca2+-binding domain IV. This reduction is 
probably due to a change in the microenvironment 
around tyrosine 138 (domain IV) since Ca2+ bin- 
ding seems to affect this microenvironment selec- 
tively [21]. 
The activation of calcineurin by the CaML pro- 
teins showed a dependence on an intact 
Ca2+-binding domain II. As shown in fig.4, 
CaML3A fully activates calcineurin as compared 
to CaM23. However, any CaML protein contain- 
ing the seven amino acid substitutions in 
Ca’+-binding domain II showed a significant 
decrease in the ability of the protein to activate 
calcineurin. CaML7, 10, 13, and 16 activate 
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Fig.2. SDS-PAGE of CaML proteins in the presence and 
absence of Ca’+. 
calcineurin about 35-50% as well as CaM23. P 
values for these four proteins are ~0.001 with 
respect to CaM23 but >0.02 with respect to each 
other. In contrast, none of the CaML proteins 
show changes in their abilities to maximally ac- 
tivate PDE or MLCK (not shown). 
CaM is a complex regulatory protein which is in- 
strumental in transmitting intracellular signals 
through Ca2+-dependent second messenger 
pathways. The protein binds Ca2+ and this com- 
plex specifically interacts with numerous different 
proteins thereby inducing activity changes. In 
order to understand how CaM can perform this 
regulatory function efficiently, the specificity of 
the interactions between CaM and the CaM- 
binding proteins must be defined. Although 
changes in the amino acid sequence in 
Ca’+-binding domains I, II, or IV are reflected in 
some of the Ca’+-dependent physical charac- 
teristics of the molecule, they do not affect the 
ability of the proteins to activate PDE or MLCK. 
In contrast, amino acid substitutions in a single 
Ca2+-binding domain (II) are sufficient to alter the 
ability of CaM to activate calcineurin significantly. 
CaML7 contains the following amino acid 
substitutions: I52-V; N53-G; N6’-S; 
T”-+S; M’l+L; K77-R and T79-S. From 
analysis of the crystal structure of CaM at 2.2 A 
[22] the most severe structural changes would be 
predicted to be N53-G and K”-R. Site 
specific mutagenesis can now be employed to pro- 
vide a definite answer. 
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Fig 3 Ca*+-dependence of enhanced tyrosine fluorescence. F, is the ratio of the relative fluorescence in the presence of Ca*+ to the . . 
relative fluorescence in the absence of Ca’+. 
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Fig.4. Activation of calcineurin by CaML proteins. Each bar 
represents the average of four representative independent 
experiments. 
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